Wednesday 18th April saw the successful start to the Nanodem immunosuppressant monitoring trial in Munich. The first two patients completed their 48 hour monitoring and further patients are planned in the next few days. In addition to monitoring the immunosuppressant cyclosporine, it was also possible to monitor the patient’s glucose.
Analysis of dialysate samples are due to be completed on a batch basis at a later date.
It is envisaged that continuous therapeutic drug monitoring of this type will lead to an improvement in drug dosing and ultimately a decrease in dosing related rejection problems post transplantation.
The technology will, in the future, be applied to a wide range of drug monitoring projects particularly those where the drug has a narrow therapeutic index
Further information regarding the Nanodem project can be found at